MetaVia reports 9.1% weight loss in obesity drug trial

May 27, 2026 8:31 AM

MetaVia Inc. (NASDAQ: MTVA) presented Phase 1 clinical trial results for its obesity drug DA-1726 at the European Association for ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found